These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10221490)

  • 1. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
    Groth CG; Bäckman L; Morales JM; Calne R; Kreis H; Lang P; Touraine JL; Claesson K; Campistol JM; Durand D; Wramner L; Brattström C; Charpentier B
    Transplantation; 1999 Apr; 67(7):1036-42. PubMed ID: 10221490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicêtre hospital experience with sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study.
    Charpentier B; Groth CG; Bäckman L; Morales JM; Calne R; Kreis H; Lang P; Touraine JL; Claesson K; Campistol JM; Durand D; Wramner L; Brattström C;
    Transplant Proc; 2003 May; 35(3 Suppl):58S-61S. PubMed ID: 12742468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
    Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts.
    MacDonald AS;
    Transplantation; 2001 Jan; 71(2):271-80. PubMed ID: 11213073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus rescue therapy for refractory rejection in renal transplantation.
    Hong JC; Kahan BD
    Transplantation; 2001 Jun; 71(11):1579-84. PubMed ID: 11435968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
    Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients.
    Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL
    Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation.
    Legendre C; Campistol JM; Squifflet JP; Burke JT;
    Transplant Proc; 2003 May; 35(3 Suppl):151S-153S. PubMed ID: 12742488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.